Using human tumor biological samples, they further demonstrated that the expression of phosphorylated ALK (p-ALK) was associated with resistance to PARP inhibitors and positively correlated with the expression of p-Tyr19-CDK9 [94]. Here, CDK9 is linked to neoplasm.